Tensha Therapeutics Receives $15,000,000 Series A Financing Round

  • Feed Type
  • Date
  • Company Name
    Tensha Therapeutics
  • Mailing Address
    55 Cambridge Parkway Cambridge, MA 02142
  • Company Description
    Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The company’s lead program, presently in preclinical development, is a first-in-class small molecule aimed at the treatment of BRD4-NUT midline carcinoma (a rare, invariably fatal cancer), acute myeloid leukemias, multiple myeloma, and other malignancies.
  • M&A Terms
  • Venture Investor
    HealthCare Ventures

Trending on Xconomy